FDA Increases Focus on Postmarketing Studies

被引：4

|

作者：

Goozner, Merrill

机构：

来源：

JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2010年 / 102卷 / 17期

关键词：

D O I：

10.1093/jnci/djq350

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：1302 / U17

页数：3

相关论文

共 50 条

[1] FDA Oversight of Postmarketing Studies
Kashoki, Mwango
Lee, Cathryn
Stein, Peter
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (12): : 1201 - 1202
[2] FDA's monitoring of postmarketing studies probed
Young, Donna
[J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2006, 63 (16) : 1485 - 1486
[3] The FDA's poor oversight of postmarketing studies
不详
[J]. LANCET, 2009, 374 (9701): : 1568 - 1568
[4] A review of pregnancy and lactation postmarketing studies required by the FDA
Krastein, Jason
Sahin, Leyla
Yao, Lynne
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 (03) : 287 - 297
[5] FDA will increase postmarketing surveillance of drugs
Tanne, JH
[J]. BRITISH MEDICAL JOURNAL, 2004, 329 (7476): : 1203 - 1203
[6] A proposal for financing postmarketing drug safety studies by augmenting FDA user fees
Carpenter, D
[J]. HEALTH AFFAIRS, 2005, 24 (06) : W5469 - W5480
[7] US FDA Postmarketing Requirements and Commitments: A Systematic Assessment of Clinical Pharmacology Studies and Their Impact on US FDA Prescribing Information
Ridge, Sarah
Guinn, Daphne
Fletcher, Elimika Pfuma
Zineh, Issam
Madabushi, Rajanikanth
Ramamoorthy, Anuradha
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (06): : 695 - 703
[8] Regulation: FDA revises postmarketing reporting requirements
Rios, Maribel
[J]. Pharmaceutical Technology, 2007, 31 (11)
[9] Postmarketing requirements for new drugs approved by the FDA
[J]. Reactions Weekly, 2022, 1895 (1) : 8 - 8
[10] US FDA posts report on postmarketing surveillance
[J]. Reactions Weekly, 2019, 1766 (1) : 3 - 3

← 1 2 3 4 5 →